Gregory D. Gromowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Gregory D. Gromowski has a total of 454 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth J. Martinez
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, USA
10 shared publications - Dominic Paquin-Proulx
U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, USA
9 shared publications - Michael Gordon Joyce
Viral Diseases Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
9 shared publications - Diane L. Bolton
U.S. Military HIV Research Program, Center for Infectious Disease Research, Walter Reed Army Institute of Research
8 shared publications Agnes Hajduczki
Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, USA
7 shared publications- Nelson L. Michael
Center for Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA
7 shared publications
Latest Publications
- Open Access
Evolutionarily distinct dengue virus type 2 with a unique type-specific neutralization determinant
Dengue viruses 1-4 (DENV1-4) mostly circulate in endemic cycles involving humans and Aedes mosquitoes. However, rare dengue outbreaks originate from non-human primates. These spillovers are caused by sylvatic virus genotypes that are closely related to endemic strains of the same serotype, but some are caused by strains that fall between the four canonical serotypes on phylogenetic trees. It is not clear whether these genotypic differences are reflected in corresponding antigenic differences. Here, we characterized the antigenic features of QML-22, a divergent strain most closely related to DENV2. On an antigenic map, QML-22 clustered with other globally representative DENV2 strains. QML-22 was not as well neutralized by antisera raised against endemic DENV2 and was better neutralized by antisera from DENV1, 3, and 4 infections than other strains of DENV2. QML-22 had a cluster of distinct amino acid residues in domain I of the envelope (E) protein, with only scattered point mutations elsewhere in the envelope. A potently neutralizing anti-DENV2 antibody that targets this site in domain I of the E protein, 3F9, had >1000-fold lower neutralization of QML-22 than other endemic DENV2 strains, whereas other cross-reactive and DENV2-specific antibodies neutralized QML-22 and endemic strains to similar titers. When antisera from non-human primates infected with QML-22 or DENV2 reference strain S16803 were depleted with the heterologous virions, homologous neutralization was unaffected but heterologous neutralization was reduced, suggesting homologous neutralization was due to distinct epitopes. Evolutionary analyses showed the 3F9 epitope was under relaxed selection pressure compared to other neutralizing epitopes and that QML-22 had unique amino acids in this epitope relative to the likely common ancestor of all DENV2. These findings provide insight into the antigenic diversification of DENV and the possible evolution of new serotypes. Author summary: Dengue viruses that are most distantly related to the four canonical serotypes originated in Borneo, suggesting this island is a possible site of early dengue virus diversification as well as continued evolution within an unidentified host species. Here, we find divergent strain QML-22 from Borneo shares many neutralizing epitopes with DENV2 but has a distinct epitope in an important region affecting potent DENV2 neutralization. This region of the virus also is variable within DENV2 and in other DENV serotypes, highlighting an important site of dengue virus diversification and evolution. The spillover threat of viruses like QML-22 remains unknown, but ecological changes in Borneo may increase this risk.
Open AccessEvolutionarily distinct dengue virus type 2 with a unique type-specific neutralization determinant
Dengue viruses 1-4 (DENV1-4) mostly circulate in endemic cycles involving humans and Aedes mosquitoes. However, rare dengue outbreaks originate from non-human primates. These spillovers are caused by sylvatic virus genotypes that are closely related to endemic strains of the same serotype, but some are caused by strains that fall between the four canonical serotypes on phylogenetic trees. It is not clear whether these genotypic differences are reflected in corresponding antigenic differences. Here, we characterized the antigenic features of QML-22, a divergent strain most closely related to DENV2. On an antigenic map, QML-22 clustered with other globally representative DENV2 strains. QML-22 was not as well neutralized by antisera raised against endemic DENV2 and was better neutralized by antisera from DENV1, 3, and 4 infections than other strains of DENV2. QML-22 had a cluster of distinct amino acid residues in domain I of the envelope (E) protein, with only scattered point mutations elsewhere in the envelope. A potently neutralizing anti-DENV2 antibody that targets this site in domain I of the E protein, 3F9, had >1000-fold lower neutralization of QML-22 than other endemic DENV2 strains, whereas other cross-reactive and DENV2-specific antibodies neutralized QML-22 and endemic strains to similar titers. When antisera from non-human primates infected with QML-22 or DENV2 reference strain S16803 were depleted with the heterologous virions, homologous neutralization was unaffected but heterologous neutralization was reduced, suggesting homologous neutralization was due to distinct epitopes. Evolutionary analyses showed the 3F9 epitope was under relaxed selection pressure compared to other neutralizing epitopes and that QML-22 had unique amino acids in this epitope relative to the likely common ancestor of all DENV2. These findings provide insight into the antigenic diversification of DENV and the possible evolution of new serotypes. Author summary: Dengue viruses that are most distantly related to the four canonical serotypes originated in Borneo, suggesting this island is a possible site of early dengue virus diversification as well as continued evolution within an unidentified host species. Here, we find divergent strain QML-22 from Borneo shares many neutralizing epitopes with DENV2 but has a distinct epitope in an important region affecting potent DENV2 neutralization. This region of the virus also is variable within DENV2 and in other DENV serotypes, highlighting an important site of dengue virus diversification and evolution. The spillover threat of viruses like QML-22 remains unknown, but ecological changes in Borneo may increase this risk.
- 29 September 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (9)
Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection
Vaccines that elicit balanced, protective immunity to all four dengue virus (DENV) types are needed to reduce the global burden of dengue disease. Achieving this goal has been a challenge for dengue vaccine developers, particularly when immunizing dengue immunologically naïve individuals. In this randomized, phase I, open-label study of 40 healthy adults, we evaluated a heterologous, tetravalent purified inactivated vaccine (PIV) prime and a tetravalent live attenuated vaccine (LAV) boost. We compared a 0, 90 day PIV/LAV prime-boost schedule to a 0, 180 day schedule. These two PIV/LAV regimens elicited similar, high, and balanced cellular and humoral immune responses to DENV 1–4, although the condensed schedule was associated with more severe adverse events. In a subsequent clinical trial [K. E. Lyke, J. V. Chua, M. Koren, H. Friberg, et al., Lancet Infect Dis 24:896–908, 2024, https://doi.org/10.1016/S1473-3099(24)00100-2 ], the PIV/LAV vaccinees were challenged with DENV-1 and most were unprotected and experienced more pronounced dengue fever-like illness than unvaccinated controls. These outcomes underscore critical gaps in our understanding of mechanistic correlates of dengue vaccine-mediated protection and disease risk. IMPORTANCE: Dengue vaccine research and development has been complicated by several factors, including an incomplete understanding of immunologic correlates of protection and immune-mediated risk of severe disease. High and balanced immunity elicited by the tetravalent purified inactivated vaccine (PIV)/live attenuated vaccine (LAV) prime-boost vaccine strategy was predicted to provide protection from dengue virus type 1 (DENV-1) challenge in a subsequent clinical study, but vaccinees were unprotected and had an unexpected increase in symptom severity compared to unvaccinated controls. Evidence of exposure to a specific DENV type by viral genome detection (e.g., by quantitative RT-PCR) in acute samples or measurement of post-exposure, type-specific antibody responses (e.g., by serum antibody depletion) are known correlates of protection. However, current methods of measuring type-specific antibody are not ideal for evaluating groups of vaccinees, even in relatively small clinical trials. Newer, high-throughput methods of determining DENV type-specific immune responses and discovery of other correlates of protection are needed to more reliably evaluate dengue vaccine candidates.
- 29 September 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (9)
Evaluation of inactivated and live attenuated, tetravalent dengue vaccine prime-boost strategies in a randomized, open-label, phase I study: implications for understanding immune correlates of protection
Vaccines that elicit balanced, protective immunity to all four dengue virus (DENV) types are needed to reduce the global burden of dengue disease. Achieving this goal has been a challenge for dengue vaccine developers, particularly when immunizing dengue immunologically naïve individuals. In this randomized, phase I, open-label study of 40 healthy adults, we evaluated a heterologous, tetravalent purified inactivated vaccine (PIV) prime and a tetravalent live attenuated vaccine (LAV) boost. We compared a 0, 90 day PIV/LAV prime-boost schedule to a 0, 180 day schedule. These two PIV/LAV regimens elicited similar, high, and balanced cellular and humoral immune responses to DENV 1–4, although the condensed schedule was associated with more severe adverse events. In a subsequent clinical trial [K. E. Lyke, J. V. Chua, M. Koren, H. Friberg, et al., Lancet Infect Dis 24:896–908, 2024, https://doi.org/10.1016/S1473-3099(24)00100-2 ], the PIV/LAV vaccinees were challenged with DENV-1 and most were unprotected and experienced more pronounced dengue fever-like illness than unvaccinated controls. These outcomes underscore critical gaps in our understanding of mechanistic correlates of dengue vaccine-mediated protection and disease risk. IMPORTANCE: Dengue vaccine research and development has been complicated by several factors, including an incomplete understanding of immunologic correlates of protection and immune-mediated risk of severe disease. High and balanced immunity elicited by the tetravalent purified inactivated vaccine (PIV)/live attenuated vaccine (LAV) prime-boost vaccine strategy was predicted to provide protection from dengue virus type 1 (DENV-1) challenge in a subsequent clinical study, but vaccinees were unprotected and had an unexpected increase in symptom severity compared to unvaccinated controls. Evidence of exposure to a specific DENV type by viral genome detection (e.g., by quantitative RT-PCR) in acute samples or measurement of post-exposure, type-specific antibody responses (e.g., by serum antibody depletion) are known correlates of protection. However, current methods of measuring type-specific antibody are not ideal for evaluating groups of vaccinees, even in relatively small clinical trials. Newer, high-throughput methods of determining DENV type-specific immune responses and discovery of other correlates of protection are needed to more reliably evaluate dengue vaccine candidates.
- Open Access
Tick-borne encephalitis virus in Dermacentor reticulatus ticks, Poland
We report the detection of tick-borne encephalitis virus (TBEV) in Dermacentor reticulatus ticks collected in Poland during the 2022 season. Both Ixodes ricinus and D. reticulatus ticks were surveilled. There was limited TBEV detection found in one pool out of 106 pools (418 ticks) that were shotgun genome sequenced. The TBEV positive tick pool consisted of N = 3 adult D. reticulatus ticks. Additional hybrid-capture sequencing of this pool resulted in the first full-length genome sequence of TBEV from this tick species. The assembled genome was classified as the European subtype through phylogenetic analysis. The new TBEV sequence is phylogenetically placed closest to a 2019 Hungarian isolate, suggesting potential viral migration or shared ancestry across nearly 1,000 km. These findings expand the known geographic range of TBEV circulation in Poland and highlight the role of D. reticulatus as an important vector of TBEV.
Open AccessTick-borne encephalitis virus in Dermacentor reticulatus ticks, Poland
We report the detection of tick-borne encephalitis virus (TBEV) in Dermacentor reticulatus ticks collected in Poland during the 2022 season. Both Ixodes ricinus and D. reticulatus ticks were surveilled. There was limited TBEV detection found in one pool out of 106 pools (418 ticks) that were shotgun genome sequenced. The TBEV positive tick pool consisted of N = 3 adult D. reticulatus ticks. Additional hybrid-capture sequencing of this pool resulted in the first full-length genome sequence of TBEV from this tick species. The assembled genome was classified as the European subtype through phylogenetic analysis. The new TBEV sequence is phylogenetically placed closest to a 2019 Hungarian isolate, suggesting potential viral migration or shared ancestry across nearly 1,000 km. These findings expand the known geographic range of TBEV circulation in Poland and highlight the role of D. reticulatus as an important vector of TBEV.
- 28 July 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (7) , e0004326
A novel method for depletion of dengue virus non-structural protein 1 antibodies to determine serotype exposure history
Nearly 4 billion people worldwide reside in dengue virus (DENV) endemic areas. Primary dengue infection generates both type-specific and cross-reactive immunity. While serotype-specific immunity provides long-term protection against homologous virus challenge, cross-reactive immunity is short-lived and, upon subsequent heterotypic exposure, can increase the risk of severe clinical outcomes. Therefore, it is critical to measure type-specific immunity. The current resource-intensive and technically demanding approach of removing antibodies using purified whole virions and subsequently assessing type-specific immunity through neutralization assays is practical only for small-scale studies. We developed a novel, straightforward method that uses transfected suspension cells stably expressing DENV non-structural protein 1 (NS1) de novo to selectively deplete targeted serotype-specific and cross-reactive NS1 antibodies from plasma and serum samples. The same cell lines are then used to establish an antibody profile of the depleted plasma to uncover type-specific serotype exposure history. This approach to antibody depletion offers several advantages over column- and bead-based depletion methods, such as (i) ease of antigenic substrate production; (ii) simplicity of the depletion procedure; and (iii) interpretability of the data. IMPORTANCE: Accurately determining dengue serotype exposure remains challenging because current serotyping methods are labor-intensive, costly, and often rely on engineered viral antigens or antibodies to capture native immune components. We developed a streamlined approach that removes NS1-specific antibodies from dengue convalescent plasma using transfected cells that express NS1 de novo . This procedure enables the characterization of the depleted sample for the antibodies left behind to understand the relative levels of different antibody specificities and uncover an individual’s dengue exposure history. The knowledge of viral antigen-antibody profiles refines the interpretation of downstream functional assays and establishes a practical framework for dissecting dengue immunity with greater precision.
- 28 July 2026
- Published by American Society for Microbiology in mSphere
- Vol. 11 (7) , e0004326
A novel method for depletion of dengue virus non-structural protein 1 antibodies to determine serotype exposure history
Nearly 4 billion people worldwide reside in dengue virus (DENV) endemic areas. Primary dengue infection generates both type-specific and cross-reactive immunity. While serotype-specific immunity provides long-term protection against homologous virus challenge, cross-reactive immunity is short-lived and, upon subsequent heterotypic exposure, can increase the risk of severe clinical outcomes. Therefore, it is critical to measure type-specific immunity. The current resource-intensive and technically demanding approach of removing antibodies using purified whole virions and subsequently assessing type-specific immunity through neutralization assays is practical only for small-scale studies. We developed a novel, straightforward method that uses transfected suspension cells stably expressing DENV non-structural protein 1 (NS1) de novo to selectively deplete targeted serotype-specific and cross-reactive NS1 antibodies from plasma and serum samples. The same cell lines are then used to establish an antibody profile of the depleted plasma to uncover type-specific serotype exposure history. This approach to antibody depletion offers several advantages over column- and bead-based depletion methods, such as (i) ease of antigenic substrate production; (ii) simplicity of the depletion procedure; and (iii) interpretability of the data. IMPORTANCE: Accurately determining dengue serotype exposure remains challenging because current serotyping methods are labor-intensive, costly, and often rely on engineered viral antigens or antibodies to capture native immune components. We developed a streamlined approach that removes NS1-specific antibodies from dengue convalescent plasma using transfected cells that express NS1 de novo . This procedure enables the characterization of the depleted sample for the antibodies left behind to understand the relative levels of different antibody specificities and uncover an individual’s dengue exposure history. The knowledge of viral antigen-antibody profiles refines the interpretation of downstream functional assays and establishes a practical framework for dissecting dengue immunity with greater precision.
- Open Access
- 10 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4494
Impact of Maternal COVID-19 Infection Versus Vaccination on Mucosal Immunity in Breastmilk
Background/Objectives: In the first months of their life, infants rely on maternal antibodies for immune protection. Breastmilk is a major source of these defenses, supplying secretory IgA, IgG, and IgM that help guard mucosal surfaces against pathogens such as SARS-CoV-2. Most studies on breastmilk immunity in the context of COVID-19 have emphasized circulating monomeric IgA, rather than the multimeric secretory IgA (sIgA) that is active at mucosal barriers. This study assessed in-depth the contribution of breastmilk antibody subtypes to SARS-CoV-2 neutralization capacity and how these profiles differ following maternal COVID-19 infection versus vaccination during pregnancy or postpartum. Methods: In this prospective cohort study, breastmilk samples were collected longitudinally from individuals who had COVID-19 during pregnancy or received COVID-19 mRNA vaccination during pregnancy or postpartum. Serological assays measured IgG, IgM, systemic IgA, and secretory IgA against SARS-CoV-2 spike and nucleocapsid antigens. Results: COVID-19 infection during pregnancy resulted in significantly higher systemic and secretory IgA levels compared to vaccination. Secretory IgA demonstrated a strong correlation with neutralization capacity. Principal component analysis revealed distinct antibody profiles in COVID-19-exposed individuals versus vaccinated cohorts, with significant overlap between pregnancy and postpartum vaccination groups. Conclusions: Although both COVID-19 vaccination and disease elicit sustained COVID-19-related antibodies in breastmilk, COVID-19 infection elicits a broader and more diverse antibody response in breastmilk, specifically with a greater secretory IgA generation. These findings support the value of maternal vaccination to safely confer mucosal immunity to neonates and the need for optimized vaccine formulations for mucosal immunity.
- 10 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4494
Open AccessImpact of Maternal COVID-19 Infection Versus Vaccination on Mucosal Immunity in Breastmilk
Background/Objectives: In the first months of their life, infants rely on maternal antibodies for immune protection. Breastmilk is a major source of these defenses, supplying secretory IgA, IgG, and IgM that help guard mucosal surfaces against pathogens such as SARS-CoV-2. Most studies on breastmilk immunity in the context of COVID-19 have emphasized circulating monomeric IgA, rather than the multimeric secretory IgA (sIgA) that is active at mucosal barriers. This study assessed in-depth the contribution of breastmilk antibody subtypes to SARS-CoV-2 neutralization capacity and how these profiles differ following maternal COVID-19 infection versus vaccination during pregnancy or postpartum. Methods: In this prospective cohort study, breastmilk samples were collected longitudinally from individuals who had COVID-19 during pregnancy or received COVID-19 mRNA vaccination during pregnancy or postpartum. Serological assays measured IgG, IgM, systemic IgA, and secretory IgA against SARS-CoV-2 spike and nucleocapsid antigens. Results: COVID-19 infection during pregnancy resulted in significantly higher systemic and secretory IgA levels compared to vaccination. Secretory IgA demonstrated a strong correlation with neutralization capacity. Principal component analysis revealed distinct antibody profiles in COVID-19-exposed individuals versus vaccinated cohorts, with significant overlap between pregnancy and postpartum vaccination groups. Conclusions: Although both COVID-19 vaccination and disease elicit sustained COVID-19-related antibodies in breastmilk, COVID-19 infection elicits a broader and more diverse antibody response in breastmilk, specifically with a greater secretory IgA generation. These findings support the value of maternal vaccination to safely confer mucosal immunity to neonates and the need for optimized vaccine formulations for mucosal immunity.
- Open Access
Production of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Background/Objectives: In response to the COVID-19 pandemic, we developed a vaccine candidate against SARS-CoV-2. Spike Ferritin Nanoparticle (SpFN) comprises 24 identical prefusion-stabilized spike proteins anchored to a self-assembled nanoparticle. Organized along the three-fold axis of the ferritin particle, eight SARS-CoV-2 spike trimers are presented per nanoparticle. Methods: Here, we describe the CGMP processes for manufacturing SpFN using transient transfection of Expi293F cells. Results: The final yield of SpFN was ~10 mg per liter of media supernatant. The resulting protein is stable in cold storage for two years at −20 °C, as well as for a month at room temperature, and can withstand multiple freeze/thaw cycles. SpFN material produced using the CGMP protocols adjuvanted with Army Liposomal Formulation-QS-21 (ALFQ) elicited potent neutralizing antibodies against WA-1, Alpha, Beta, and Delta variants in mice as measured by a pseudovirus neutralization assay. Conclusions: This work demonstrates rapid development and scaled-up production of clinical-grade SARS-CoV-2 vaccine protein material, allowing permissive storage and transport conditions, and serves as a framework for recombinant protein production for future emergent pathogens.
Open AccessProduction of Clinical-Grade SARS-CoV-2 Spike Ferritin Nanoparticle Protein Immunogen by Transient Transfection
Background/Objectives: In response to the COVID-19 pandemic, we developed a vaccine candidate against SARS-CoV-2. Spike Ferritin Nanoparticle (SpFN) comprises 24 identical prefusion-stabilized spike proteins anchored to a self-assembled nanoparticle. Organized along the three-fold axis of the ferritin particle, eight SARS-CoV-2 spike trimers are presented per nanoparticle. Methods: Here, we describe the CGMP processes for manufacturing SpFN using transient transfection of Expi293F cells. Results: The final yield of SpFN was ~10 mg per liter of media supernatant. The resulting protein is stable in cold storage for two years at −20 °C, as well as for a month at room temperature, and can withstand multiple freeze/thaw cycles. SpFN material produced using the CGMP protocols adjuvanted with Army Liposomal Formulation-QS-21 (ALFQ) elicited potent neutralizing antibodies against WA-1, Alpha, Beta, and Delta variants in mice as measured by a pseudovirus neutralization assay. Conclusions: This work demonstrates rapid development and scaled-up production of clinical-grade SARS-CoV-2 vaccine protein material, allowing permissive storage and transport conditions, and serves as a framework for recombinant protein production for future emergent pathogens.
- Open Access
- 3 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine-elicited antibodies highlights the need to develop next-generation vaccine candidates that confer broad protection. Here we describe the antibody response induced by the SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine candidate adjuvanted with the Army Liposomal Formulation including QS21 (ALFQ) in non-human primates. By isolating and characterizing several monoclonal antibodies directed against the Spike Receptor Binding Domain (RBD), N-Terminal Domain (NTD), or the S2 Domain, we define the molecular recognition of vaccine-elicited cross-reactive monoclonal antibodies (mAbs) elicited by SpFN. We identify six neutralizing antibodies with broad sarbecovirus cross-reactivity that recapitulate serum polyclonal antibody responses. In particular, RBD mAb WRAIR-5001 binds to the conserved cryptic region with high affinity to sarbecovirus clades 1 and 2, including Omicron variants, while mAb WRAIR-5021 offers complete protection from B.1.617.2 (Delta) in a murine challenge study. Our data further highlight the ability of SpFN vaccination to stimulate cross-reactive B cells targeting conserved regions of the Spike with activity against SARS CoV-1 and SARS-CoV-2 variants.
- 3 January 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-19
Open AccessDiverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques
The repeat emergence of SARS-CoV-2 variants of concern (VoC) with decreased susceptibility to vaccine-elicited antibodies highlights the need to develop next-generation vaccine candidates that confer broad protection. Here we describe the antibody response induced by the SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine candidate adjuvanted with the Army Liposomal Formulation including QS21 (ALFQ) in non-human primates. By isolating and characterizing several monoclonal antibodies directed against the Spike Receptor Binding Domain (RBD), N-Terminal Domain (NTD), or the S2 Domain, we define the molecular recognition of vaccine-elicited cross-reactive monoclonal antibodies (mAbs) elicited by SpFN. We identify six neutralizing antibodies with broad sarbecovirus cross-reactivity that recapitulate serum polyclonal antibody responses. In particular, RBD mAb WRAIR-5001 binds to the conserved cryptic region with high affinity to sarbecovirus clades 1 and 2, including Omicron variants, while mAb WRAIR-5021 offers complete protection from B.1.617.2 (Delta) in a murine challenge study. Our data further highlight the ability of SpFN vaccination to stimulate cross-reactive B cells targeting conserved regions of the Spike with activity against SARS CoV-1 and SARS-CoV-2 variants.
- Open Access
- 15 September 2023
- Published by Springer Nature in Research Square
Preexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human Challenge
Dengue Human Infection Models (DHIM) are needed to down-select dengue vaccine candidates and establish tetravalent efficacy before advanced clinical field trials. As part of a randomized heterologous prime-boost vaccine strategy, participants received a tetravalent dengue (TDEN) Purified Inactivated Vaccine (PIV) prime followed by a TDEN Live Attenuated Vaccine (LAV) boost at 28, 90 or 180 days. Vaccinated participants (n = 6) aged 18–50 years, with detectable pre-challenge TDEN antibody titers, and flavivirus-naïve control participants (n = 4) were inoculated with DENV-1 strain 45AZ5, 27–65 months following booster dosing. Daily quantitative PCR detected DENV-1 RNA in nine of 10 participants (5/6 vaccinees and 4/4 controls). The mean onset of RNAemia occurred on day 5 (range 5–6) in vaccinees versus day 8 (range 7–10) in controls, P = 0.007, with a trend towards reduced RNAemia duration in vaccinees (8.2 days vs. 10.5, P = 0.056). Mild to moderate symptoms, leukopenia, and transaminitis were commonly observed. Severe adverse events were detected only in vaccinees, including fever > 102.1°F (n = 3) and headache (n = 1), with one transient Grade 4 AST. Immunologic and transcriptomic analyses revealed vaccinees developed rapid and more robust upregulation of pathogen-induced gene markers of inflammatory innate and effector responses, in the setting of pre-existing antibodies and in vitro evidence of antibody-dependent enhancement, compared to naïve controls. We conclude that TDEN-PIV-primed, TDEN-LAV-boosted participants were unprotected against DENV-1 infection and further, showed increased clinical, immunologic, and transcriptomic evidence of inflammation potentially mediated by preexisting infection-enhancing antibodies. ClinicalTrials.gov identifier: NCT04786457.
- 15 September 2023
- Published by Springer Nature in Research Square
Open AccessPreexisting Enhancing Antibodies in Vaccinated Participants Accelerate Dengue Virus 1 Infection Following Live Virus Human Challenge
Dengue Human Infection Models (DHIM) are needed to down-select dengue vaccine candidates and establish tetravalent efficacy before advanced clinical field trials. As part of a randomized heterologous prime-boost vaccine strategy, participants received a tetravalent dengue (TDEN) Purified Inactivated Vaccine (PIV) prime followed by a TDEN Live Attenuated Vaccine (LAV) boost at 28, 90 or 180 days. Vaccinated participants (n = 6) aged 18–50 years, with detectable pre-challenge TDEN antibody titers, and flavivirus-naïve control participants (n = 4) were inoculated with DENV-1 strain 45AZ5, 27–65 months following booster dosing. Daily quantitative PCR detected DENV-1 RNA in nine of 10 participants (5/6 vaccinees and 4/4 controls). The mean onset of RNAemia occurred on day 5 (range 5–6) in vaccinees versus day 8 (range 7–10) in controls, P = 0.007, with a trend towards reduced RNAemia duration in vaccinees (8.2 days vs. 10.5, P = 0.056). Mild to moderate symptoms, leukopenia, and transaminitis were commonly observed. Severe adverse events were detected only in vaccinees, including fever > 102.1°F (n = 3) and headache (n = 1), with one transient Grade 4 AST. Immunologic and transcriptomic analyses revealed vaccinees developed rapid and more robust upregulation of pathogen-induced gene markers of inflammatory innate and effector responses, in the setting of pre-existing antibodies and in vitro evidence of antibody-dependent enhancement, compared to naïve controls. We conclude that TDEN-PIV-primed, TDEN-LAV-boosted participants were unprotected against DENV-1 infection and further, showed increased clinical, immunologic, and transcriptomic evidence of inflammation potentially mediated by preexisting infection-enhancing antibodies. ClinicalTrials.gov identifier: NCT04786457.
- Open Access
- 4 July 2023
- Published by Elsevier in EBioMedicine
- Vol. 94, 104683
Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population
- 4 July 2023
- Published by Elsevier in EBioMedicine
- Vol. 94, 104683
Open AccessHumoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population
- 7 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (699) , eabq6517
Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets
Zika virus (ZIKV) infection during pregnancy causes severe developmental defects in newborns, termed congenital Zika syndrome (CZS). Factors contributing to a surge in ZIKV-associated CZS are poorly understood. One possibility is that ZIKV may exploit the antibody-dependent enhancement of infection mechanism, mediated by cross-reactive antibodies from prior dengue virus (DENV) infection, which may exacerbate ZIKV infection during pregnancy. In this study, we investigated the impact of prior DENV infection or no DENV infection on ZIKV pathogenesis during pregnancy in a total of four female common marmosets with five or six fetuses per group. The results showed that negative-sense viral RNA copies increased in the placental and fetal tissues of DENV-immune dams but not in DENV-naïve dams. In addition, viral proteins were prevalent in endothelial cells, macrophages, and neonatal Fc receptor–expressing cells in the placental trabeculae and in neuronal cells in the brains of fetuses from DENV-immune dams. DENV-immune marmosets maintained high titers of cross-reactive ZIKV-binding antibodies that were poorly neutralizing, raising the possibility that these antibodies might be involved in the exacerbation of ZIKV infection. These findings need to be verified in a larger study, and the mechanism involved in the exacerbation of ZIKV infection in DENV-immune marmosets needs further investigation. However, the results suggest a potential negative impact of preexisting DENV immunity on subsequent ZIKV infection during pregnancy in vivo.
- 7 June 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (699) , eabq6517
Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets
Zika virus (ZIKV) infection during pregnancy causes severe developmental defects in newborns, termed congenital Zika syndrome (CZS). Factors contributing to a surge in ZIKV-associated CZS are poorly understood. One possibility is that ZIKV may exploit the antibody-dependent enhancement of infection mechanism, mediated by cross-reactive antibodies from prior dengue virus (DENV) infection, which may exacerbate ZIKV infection during pregnancy. In this study, we investigated the impact of prior DENV infection or no DENV infection on ZIKV pathogenesis during pregnancy in a total of four female common marmosets with five or six fetuses per group. The results showed that negative-sense viral RNA copies increased in the placental and fetal tissues of DENV-immune dams but not in DENV-naïve dams. In addition, viral proteins were prevalent in endothelial cells, macrophages, and neonatal Fc receptor–expressing cells in the placental trabeculae and in neuronal cells in the brains of fetuses from DENV-immune dams. DENV-immune marmosets maintained high titers of cross-reactive ZIKV-binding antibodies that were poorly neutralizing, raising the possibility that these antibodies might be involved in the exacerbation of ZIKV infection. These findings need to be verified in a larger study, and the mechanism involved in the exacerbation of ZIKV infection in DENV-immune marmosets needs further investigation. However, the results suggest a potential negative impact of preexisting DENV immunity on subsequent ZIKV infection during pregnancy in vivo.